Analysts trim targets as VST slips 2.4% into Q3 results
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Vistra Corp. shed 2.4% over the past week to close at $146.66, underperforming its closest peers at a moment when the Street is converging on a shared view: the thesis remains intact, but the number has come down.
Three separate analyst actions this week all landed in the same place. BofA's Julien Dumoulin-Smith clipped his target from $196 to $194 while keeping a Buy rating. Wells Fargo lowered from $212 to $198, also maintaining Overweight. Scotiabank cut the furthest, from $207 to $189, while holding Sector Outperform. None of these are downgrades, and two new initiations arrived earlier in October: HSBC started coverage with a Buy at $190, and CIBC initiated at Outperform with a $201 target. The mean consensus target now sits at $208, a 42% premium to the current price, placing Vistra at the top of the analyst-recommendation factor percentile at 99. Morgan Stanley, which moved its target only marginally from $227 to $226 last week, remains the most bullish voice on the Street.
The bear case the analysts are navigating is real. Commodity price swings hit Vistra's adjusted EBITDA by an estimated $1.6 billion, and the stock remains roughly 30% below its peak. The bull response is that the Cogentrix acquisition lifted EBITDA forecasts by 7%, management is targeting free cash flow conversion at or above 60% of adjusted EBITDA from 2026, and the EV/EBITDA multiple of 9.1 looks modest against that backdrop. Price-to-book has expanded to 7.6, up nearly 0.85 points over 30 days, reflecting a market that has re-rated the asset base higher even as the share price has pulled back. The EPS surprise factor rank sits at just 20, suggesting the company has been coming in below consensus expectations, which gives the bear case some factual traction.
Lending market conditions give no additional comfort to shorts. Availability is extremely loose at 3,514%, meaning shares to borrow far exceed what is currently borrowed. Short interest has drifted down 10.7% over the past month to 3.1% of free float, and borrowing costs, while up 6% on the week and 43% over the month, remain negligible at 0.50%. The borrow market is simply not pricing in any squeeze dynamics. Options positioning is flat against its recent average: the put/call ratio of 1.09 is essentially at its 20-day mean of 1.09, with a z-score near zero. There is no clear directional lean in derivatives.
The insider picture set out in last week's note has not changed materially. CEO James Burke's open-market purchases at around $135 in late August remain the standout discretionary signal. The stock now trades at $146.66, above those entry prices. CFO Moldovan and EVP Hudson have continued selling under pre-scheduled 10b5-1 plans, which are compensation mechanics rather than conviction. The net 90-day insider value is minus $15.5 million, dominated by those plan sales. BlackRock holds 8.7% of shares, the Qatar Investment Authority disclosed a 5.5% passive stake as of August 2025, and Vanguard entities collectively hold roughly 12%. None of the 13D/G filings on the register carry activist intent; all are passive disclosures around the 5% threshold, and stakes are as last disclosed.
Alt data from MSHA registers Q2 safety violations at the smallest level in nine years, at just four violations, alongside the largest Q2 employee hours worked in two years at 226,000 hours. EPA data shows Vistra's gross capacity factor rose for four consecutive months through June, though June itself was the lowest June reading on record since 2024. None of these datasets have been tested as leading indicators for the company's financials, so they describe operational context rather than pointing to the earnings print.
The Q3 release is scheduled for November 5. The two most recent earnings prints produced modest next-day moves: plus 1.1% after August's report and minus 1.3% after May's, with five-day drifts of plus 4.8% and plus 2.4% respectively. The question heading into next week is whether the spread of target cuts, none of which crossed into rating downgrades, reflects the Street getting ahead of a softer print or simply marking numbers to the current share price.
Stocks in this article
See the live data behind this article on ORTEX.
Open VST on ORTEX →How this article was generated
- Generated
- 28 Oct 2026, 20:19
- Data as of
- 28 Oct 2026, 20:18
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.